Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Trial details
- Registry ID
- NCT03110562
- Phase
- Phase 3
The FDA approved Bortezomib (Velcade) on 13 May 2003.
Drug identity checked against registry records
Also recorded as Velcade; Velcade®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562 | KPTI | Phase 3 | Completed | 2020-02-18Actual |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475 | KPTI | Phase 2 | Recruiting | 2028-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2003-05-13Day | Bortezomib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021602", "applicant_as_listed_by_fda": "TAKEDA PHARMS USA", "brand_names": ["VELCADE"], "active_ingredients": ["BORTEZOMIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20030513", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |